HDAC3 inhibition protects against peripheral and central alterations in an animal model of obesity
- PMID: 37698830
- DOI: 10.1007/s43440-023-00528-7
HDAC3 inhibition protects against peripheral and central alterations in an animal model of obesity
Abstract
Background: Obesity is a multifactorial disease with epigenetic manifestations that increases the prevalence of associated comorbidities such as metabolic syndrome, cardiovascular dysfunction, and major depression disorder. Given the aforementioned, a search for new pharmacological alternatives for the treatment of this disease is necessary. The current study aimed to evaluate the effects of histone deacetylase-3 (HDAC3) inhibition caused by RGFP966 (a benzamide-type HDAC inhibitor selective for HDAC3) administration, in an animal model of obesity induced by high-fat diet (HFD).
Methods: Adult male mice C57BJ/6 were fed with a normal pellet diet (NPD) or HFD for 120 days. The HDAC3 inhibitor (RGFP966; 10 mg/kg; sc) was administered on the 91st to 120th day of the experiment (per 30 days). After the last inhibitor administration, animals were euthanized, blood was collected, and the hippocampus was removed for biochemical determinations.
Results: In an overall manner, the administration of RGFP966 protected against changes in body weight gain, glucose, insulin, lipid profile, adipokines, and increase of hippocampal proinflammatory cytokines levels caused by HFD.
Conclusion: Therefore, HDAC3 inhibition can represent a promising pharmacological target for the treatment of obesity.
Keywords: Epigenetic; Metabolism; Neuroinflammation; Nutrition; Obesity.
© 2023. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Similar articles
-
RGFP966 is protective against lipopolysaccharide-induced depressive-like behaviors in mice by inhibiting neuroinflammation and microglial activation.Int Immunopharmacol. 2021 Dec;101(Pt B):108259. doi: 10.1016/j.intimp.2021.108259. Epub 2021 Oct 16. Int Immunopharmacol. 2021. PMID: 34666303
-
The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.PLoS One. 2016 Mar 31;11(3):e0152498. doi: 10.1371/journal.pone.0152498. eCollection 2016. PLoS One. 2016. PMID: 27031333 Free PMC article.
-
Histone Deacetylase 3 Inhibition Decreases Cerebral Edema and Protects the Blood-Brain Barrier After Stroke.Mol Neurobiol. 2023 Jan;60(1):235-246. doi: 10.1007/s12035-022-03083-z. Epub 2022 Oct 18. Mol Neurobiol. 2023. PMID: 36258136 Free PMC article.
-
Sodium Butyrate Protects -Against High Fat Diet-Induced Cardiac Dysfunction and Metabolic Disorders in Type II Diabetic Mice.J Cell Biochem. 2017 Aug;118(8):2395-2408. doi: 10.1002/jcb.25902. Epub 2017 Apr 25. J Cell Biochem. 2017. PMID: 28109123 Free PMC article.
-
Targeting HDAC3 Activity with RGFP966 Protects Against Retinal Ganglion Cell Nuclear Atrophy and Apoptosis After Optic Nerve Injury.J Ocul Pharmacol Ther. 2018 Apr;34(3):260-273. doi: 10.1089/jop.2017.0059. Epub 2017 Dec 6. J Ocul Pharmacol Ther. 2018. PMID: 29211617 Free PMC article.